Master Glyburide and Glipizide (2nd Generation Sulfonylureas) with Picmonic for Medicine

Second generation sulfonylureas have largely replaced the first generation agents based on their increased potency and fewer drug-drug interactions. The prescribed dosages of these drugs are much lower than first generation agents due to their increased potency.

Second generation sulfonylureas stimulate pancreatic islet cells to release insulin. These drugs depolarize the cell membrane by blocking ATP-sensitive potassium channels. As the membrane depolarizes, an influx of calcium enters and drives insulin out of the cells.

Second generation sulfonylureas stimulate pancreatic islet cells to release insulin. These drugs depolarize the cell membrane by blocking ATP-sensitive potassium channels. As the membrane depolarizes, an influx of calcium enters and drives insulin out of the cells.

Second generation sulfonylureas stimulate the pancreatic islet cells to increase insulin release. These drugs are indicated for patients with type 2 diabetes with some pancreatic function. Patients with type 1 diabetes lack the ability to produce insulin and do not benefit from these drugs. Glyburide and glipizide may be used alone or in conjunction with other drug therapy. However, these medications should not replace proper diet and exercise for optimal glucose management.

Since second generation sulfonylureas cause increased insulin release, the patient may develop hypoglycemia (refer to Picmonic "Hypoglycemia Assessment"). Because these medications are processed by the liver and kidneys, patients with hepatic or renal dysfunction are more susceptible to hypoglycemia.

Second generation sulfonylureas are much more potent than first generation agents. Due to their increased potency, lower dosages are needed to elicit the same therapeutic effects. Decreasing the medication dose also decreases risk of side effects.

Avoid the use of beta blockers while taking second generation sulfonylureas because of their ability to mask sympathetic responses related to decreasing glucose levels. If the patient does not have noticeable symptoms, they may not be able to prevent severe hypoglycemia. Beta blockers also decrease the effect of sulfonylureas by suppressing the release of insulin.

Instruct the patient to abstain from alcohol while taking second generation sulfonylureas. Although disulfiram-like reactions occur more often with first generation sulfonylureas, they should be monitored for with second generation medications. Alcohol potentiates the hypoglycemic effects of the sulfonylurea medications.

Second generation sulfonylureas (except glyburide) should be avoided while pregnant or breastfeeding. Exposure to these drugs prior to delivery causes severe hypoglycemia in newborns lasting up to 10 days. These medications are excreted into breast milk and lead to hypoglycemia in the infant. Insulin may be substituted to control type 2 diabetes in patients who are pregnant or nursing. It is important to note that breastfeeding women should be counseled on the use of breastfeeding and risk of hypoglycemia if continuing the use of glyburide.